Efficacy and safety of fruquintinib in combination with sintilizumab and SBRT in the treatment of oligonadenocarcinoma progression in the stomach or gastroesophageal junction
Have fully understood this study and voluntarily signed the informed consent form;
Be at least 18 years old, regardless of gender;
Have histologically and/or cytologically confirmed metastatic or locally advanced gastric or gastroesophageal junction adenocarcinoma, and have experienced at least one failure of systemic treatment (Note: The previously accepted systemic treatment regimens in this protocol include chemotherapy alone or in combination with multiple drugs, or immunotherapy combined with chemotherapy, or failure after receiving anti-HER-2 targeted therapy for HER-2 positive cases. Failure is defined as intolerable toxic side effects, disease progression during treatment, or recurrence after the end of treatment);
Have an Eastern Cooperative Oncology Group (ECOG) performance status score of 0-1;
Have previously received treatment with VEGF or VEGFR inhibitors;
Have received live vaccines within 4 weeks before enrollment or are likely to receive them during the study period;
Have had an autoimmune disease or a history of autoimmune disease within 4 weeks before enrollment;
Have previously received allogeneic bone marrow transplantation or organ transplantation;
Single group
Fruquintinib Combined with Sintilimab and Stereotactic Body Radiation Therapy
Drugno other intervention
Progression-free survival (PFS)
Click on the lead sponsor to view all of their trials.
Queling Liu
Lead sponsor
Second Affiliated Hospital of Nanchang University
Sponsor institution
This trial is not recruiting at the moment. You can still explore other options:
